Skip to content
Search

Latest Stories

Vaccine task force head says vaccinating all of UK 'not going to happen'

Kate Bingham, head of the UK's vaccine task force, said that vaccinating everyone in the country for the coronavirus was ‘not going to happen’.

In an interview with the Financial Times she said: "There's going to be no vaccination of people under 18. It's an adult-only vaccine, for people over 50, focusing on health workers and care home workers and the vulnerable."


Bingham’s comments follow that of Prime Minister Boris Johnson who on Sunday (Oct 4) said he expected the next few months of the Covid-19 pandemic to be bumpy, but that things would look radically different in the spring.

“People keep talking about time to vaccinate the whole population, but that is misguided,” she said to the FT, adding that vaccinating healthy people, who are much less likely to have severe outcomes from Covid-19, “could cause them some freak harm”.

The UK suffered Europe’s worst death toll from the virus with the current total standing at over 42,300.

The Times, citing government scientists, reported last week that a mass roll-out of a Covid-19 vaccine in the UK could be finished in as little as three months, adding that health officials estimate that every adult could receive a dose of the vaccine within six months.

Bingham said the government was aiming to vaccinate about 30 million people, compared with a UK population of about 67 million, if a successful vaccine against Covid-19 was found, according to the FT.

More For You

First daily pill for endometriosis to be available on NHS

Instead of travelling to clinics for injections, endometriosis patients can take a daily tablet at home

Getty Images

New endometriosis pill approved for NHS use, but only few patients will benefit

The National Institute for Health and Care Excellence (NICE) has approved a new pill for the treatment of endometriosis, providing hope for thousands of women affected by the debilitating condition.

The pill, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), is the first long-term daily pill approved for use in the UK to treat endometriosis, and it is expected to help about 1,000 patients every year.

Keep ReadingShow less
​RPS urges its members and fellows to vote in favour of Royal College for “a stronger, louder voice”

The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025.

Getty Images

Royal College voting begins: A historic moment in the profession’s evolution

Becoming a royal college will ensure pharmacy profession gains the recognition and authority it deserves, says RPS president Professor Claire Anderson.

Starting today (13), members and fellows of the Royal Pharmaceutical Society (RPS) will begin voting on the proposed changes to its Royal Charter, marking the beginning of a historic shift toward becoming the Royal College of Pharmacy.

Keep ReadingShow less
GPs to play crucial role in transforming Wales’ health service

Jeremy Miles

(Photo credit: www.gov.wales )

Strengthening GPs’ role key to transforming healthcare - Jeremy Miles

Welsh health secretary Jeremy Miles has recognised the need to transform health services and bring healthcare closer to home.

Speaking at the recent Welsh Local Medical Committees Conference, he emphasised that strengthening the role of GPs would be crucial in improving patient healthcare and tackling NHS waiting lists.

Keep ReadingShow less
NPA and IPA urge NHS England to release pharmacy economic analysis immediately

Pharmacy bodies call for transparency on the funding gap amid ongoing contract negotiations.

Getty Images

Pharmacy bodies demand immediate release of economic analysis

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) have jointly written to NHS England, demanding the immediate release of the independent economic analysis of pharmacy finances commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

Keep ReadingShow less